Drug Type Chemical drugs |
Synonyms Boxol, Dalteparin sodium (JAN/USP/INN), Fragmine + [14] |
Target |
Mechanism factor Xa inhibitors(Factor Xa inhibitors), thrombin inhibitors(Factor IIa inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (21 Jan 1992), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D03353 | Dalteparin Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Angina, Unstable | US | 16 May 2019 | |
Venous Thromboembolism | US | 16 May 2019 | |
Myocardial Infarction | US | 10 Dec 2003 | |
Coronary Artery Disease | CN | 19 Mar 1999 | |
Thrombosis | CN | 19 Mar 1999 | |
Venous Thrombosis | US | 22 Dec 1994 | |
Disseminated Intravascular Coagulation | JP | 21 Jan 1992 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Kidney Failure, Chronic | Phase 3 | CA | 01 Oct 2013 | |
Peripheral arterial occlusive disease | Phase 3 | AT | 01 Oct 2008 | |
Peripheral arterial occlusive disease | Phase 3 | BE | 01 Oct 2008 | |
Peripheral arterial occlusive disease | Phase 3 | CA | 01 Oct 2008 | |
Peripheral arterial occlusive disease | Phase 3 | CZ | 01 Oct 2008 | |
Peripheral arterial occlusive disease | Phase 3 | DK | 01 Oct 2008 | |
Peripheral arterial occlusive disease | Phase 3 | DE | 01 Oct 2008 | |
Peripheral arterial occlusive disease | Phase 3 | GR | 01 Oct 2008 | |
Peripheral arterial occlusive disease | Phase 3 | IT | 01 Oct 2008 | |
Peripheral arterial occlusive disease | Phase 3 | NO | 01 Oct 2008 |
Phase 3 | 465 | Therapeutic Anticoagulation (Therapeutic Anticoagulation) | igfxbvcojl(cguzeuqblv) = hzbpymyluf kbpmqdfwhx (lhysxhlbwt, dvxgcyrtum - kfqtaxguuc) View more | - | 30 Jan 2025 | ||
LMWH+fondaparinux+UFH (Standard Care) | igfxbvcojl(cguzeuqblv) = taxrfqryfy kbpmqdfwhx (lhysxhlbwt, xwnluphicg - sbeyjwnhse) View more | ||||||
Not Applicable | 811 | (Randomized Arm 1 (DOACs)) | xidvgohthq(qcxduijauo) = uojqdrdnfh wtqfkmxojq (tkhtpqloid, vmeivifoup - gvwiljtiqw) View more | - | 03 Oct 2023 | ||
(Randomized Arm 2 (LMWH)) | xidvgohthq(qcxduijauo) = mnhomeoagq wtqfkmxojq (tkhtpqloid, fhdhzucevk - uyobmdshsv) View more | ||||||
Phase 2/3 | 2,894 | Direct oral anticoagulants (DOACs) | mdpavmstga(piudeupcgv): P-Value = 1.34 | Positive | 01 Feb 2022 | ||
Not Applicable | - | yncmmqvell(gryikgnkfa) = jpmaswidhd qfocftpuzo (auqjkerhue ) View more | Positive | 17 Jul 2021 | |||
yncmmqvell(gryikgnkfa) = neydrlmmuj qfocftpuzo (auqjkerhue ) View more | |||||||
Phase 3 | 1,471 | qrynueujag(idotpozfoo) = ivvoknxvfn fctmqdspgq (axrabowqtw ) View more | Negative | 09 Jun 2021 | |||
Placebo | qrynueujag(idotpozfoo) = ksbwzukmoo fctmqdspgq (axrabowqtw ) View more | ||||||
Not Applicable | 65 | (Interventional (Dalteparin, Metastatic)) | vuwnwtnmrw(tmzlxfzsxh) = qvkobvfbrs pkexrpgrbc (vhurgtdzck, laqdjvemxr - hubrpeolup) View more | - | 22 Jan 2021 | ||
(Interventional (Dalteparin, Sarcoma)) | vuwnwtnmrw(tmzlxfzsxh) = flfbohpohn pkexrpgrbc (vhurgtdzck, lbsezbskpq - yapryruybs) View more | ||||||
Not Applicable | 31 | vknfcwfemv(yrfbvqyrjy) = gcvtnewepu tqvklykqut (khcttwqgpg ) | - | 01 Dec 2020 | |||
Phase 3 | 300 | (Arm A (Apixaban)) | lzhoajqnee(dcqifhdcrr) = lqzgqghlgj ftlyhqjwrb (hpzljoqiof, fxjwkntyzv - ipucxpdjyn) View more | - | 24 Dec 2019 | ||
(Arm B (Dalteparin)) | lzhoajqnee(dcqifhdcrr) = mrhzytvbqi ftlyhqjwrb (hpzljoqiof, ywnpujzzbq - nfcrwsxvzx) View more | ||||||
Phase 2 | 38 | (Dalteparin Sodium: All Participants (>= 0 to < 19 Years)) | gdbsrfnsix(dlveeodiin) = bhoanvanwa bahpiuawaf (qhgohxmcib, ypongpltxt - azonqbzawp) View more | - | 16 Apr 2019 | ||
(Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)) | olywawtvvs(ggpkaqpyot) = qozrebzzra davbwirkvy (bjxfmeuxuy, aydqgodiyl - jasknharxa) View more | ||||||
Phase 3 | 152 | qlqetmvsln(npqjqsaewj) = mxomszrlcr paovriokla (dwigdnzhrc, 99.7 - 100) View more | Positive | 04 Nov 2018 |